U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H27ClN2O.ClH
Molecular Weight 455.419
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LOFEPRAMINE HYDROCHLORIDE

SMILES

Cl.CN(CCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2)CC(=O)C4=CC=C(Cl)C=C4

InChI

InChIKey=ZWZIQPOLMDPIQM-UHFFFAOYSA-N
InChI=1S/C26H27ClN2O.ClH/c1-28(19-26(30)22-13-15-23(27)16-14-22)17-6-18-29-24-9-4-2-7-20(24)11-12-21-8-3-5-10-25(21)29;/h2-5,7-10,13-16H,6,11-12,17-19H2,1H3;1H

HIDE SMILES / InChI
Lofepramine is a tricyclic antidepressant that is structurally similar to imipramine and is extensively metabolised to desipramine. In the absence of other major pharmacological effects it appears that its antidepressant activity stems from the facilitation of noradrenergic neurotransmission by uptake inhibition, and possibly by the additional facilitation of serotoninergic neurotransmission. The overall therapeutic efficacy of lofepramine is comparable to that of imipramine, amitriptyline, clomipramine, maprotiline and mianserin in patients with depression of varying severity, and coexisting anxiety. Lofepramine is a strong inhibitor of norepinephrine reuptake (Ki=5.4 nM) and a moderate inhibitor of serotonin reuptake (Ki=70 nM). It is a weak-intermediate level antagonist of the muscarinic acetylcholine receptors.Lofepramine is licensed for the treatment of depression in the United Kingdom.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Lofepramine

Approved Use

Lofepramine Tablets are used to treat the symptoms of depression. Common symptoms include feelings of worthlessness or deep sadness, difficulty with everyday tasks, sleeping too much or not being able to sleep, and feeling anxious.
PubMed

PubMed

TitleDatePubMed
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
1997 Dec 11
The effect of lofepramine and other related agents on the motility of Tetrahymena pyriformis.
2002 Mar 10
Nonpharmacological treatments for anxiety disorders.
2002 Sep
The promises and pitfalls of reboxetine.
2003 Winter
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder.
2010
Tricyclic antidepressants and headaches: systematic review and meta-analysis.
2010 Oct 20
Patents

Sample Use Guides

The recommended dose for adults is one tablet to be taken 2 or 3 times a day
Route of Administration: Oral
In Vitro Use Guide
The mean value for the inhibition constant (Ki) for lofepramine in human parotid gland was 285 nM.
Name Type Language
LOFEPRAMINE HYDROCHLORIDE
JAN   MART.   MI   USAN   WHO-DD  
USAN  
Official Name English
4'-CHLORO-2-((3-(10,11-DIHYDRO-5H-DIBENZ(B,F)AZEPIN-5-YL)PROPYL)METHYLAMINO)ACETOPHENONE MONOHYDROCHLORIDE
Systematic Name English
Lofepramine hydrochloride [WHO-DD]
Common Name English
LOFEPRAMINE HYDROCHLORIDE [MART.]
Common Name English
LOFEPRAMINE HYDROCHLORIDE [USAN]
Common Name English
ETHANONE, 1-(4-CHLOROPHENYL)-2-((3-(10,11-DIHYDRO-5H-DIBENZ(B,F)AZEPIN-5-YL)PROPYL)METHYLAMINO)-, MONOHYDROCHLORIDE
Common Name English
LOFEPRAMINE HCL
Common Name English
4'-CHLORO-2-((3-(10,11-DIHYDRO-5H-DIBENZ(B,F)AZEPIN-5-YL)PROPYL)METHYLAMINO)ACETOPHENONE HYDROCHLORIDE
Systematic Name English
AMPLIT
Brand Name English
LOFEPRAMINE HYDROCHLORIDE [MI]
Common Name English
WHR-2908A
Code English
LOFEPRAMINE HYDROCHLORIDE [JAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C87616
Created by admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
PRIMARY
ECHA (EC/EINECS)
248-002-2
Created by admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
PRIMARY
SMS_ID
100000087617
Created by admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
PRIMARY
MERCK INDEX
m6884
Created by admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
PRIMARY Merck Index
CHEBI
31780
Created by admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
PRIMARY
USAN
Y-39
Created by admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
PRIMARY
FDA UNII
Z24K96F991
Created by admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
PRIMARY
EPA CompTox
DTXSID9047833
Created by admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
PRIMARY
RXCUI
6294
Created by admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
PRIMARY RxNorm
CAS
26786-32-3
Created by admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
PRIMARY
PUBCHEM
33611
Created by admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
PRIMARY
ChEMBL
CHEMBL87708
Created by admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
PRIMARY
EVMPD
SUB02965MIG
Created by admin on Fri Dec 15 15:17:30 GMT 2023 , Edited by admin on Fri Dec 15 15:17:30 GMT 2023
PRIMARY